시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 분변 미생물총 이식(FMT) 시장 보고서(2024년)
Fecal Microbiota Transplantation (FMT) Global Market Report 2024
상품코드 : 1619579
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 5,000 ￦ 7,095,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 7,500 ￦ 10,643,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 10,000 ￦ 14,191,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

분변 미생물총 이식(FMT) 시장 규모는 향후 몇 년동안 강력한 성장세를 보일 것으로 예상되며, 2028년까지 7.0%의 연평균 복합 성장률(CAGR)로 11억 2,000만 달러에 달할 것으로 예상됩니다. 예측 기간 동안의 성장은 클로스트리듐 디피실 감염(CDI) 유병률 증가, 염증성 장 질환 유병률 증가, 연구개발 활동 증가, 고령 인구 증가, 의료 인프라 확대에 기인할 것으로 보입니다. 이 시기의 주요 동향으로는 기증자 스크리닝 및 대변 준비를 위한 표준화된 프로토콜 개발, 마이크로바이옴 분석의 발전, 대변 처리 기술의 개선, 혁신적인 전달 방법, 합성 또는 표준화된 마이크로바이옴 기반 제품 개발 등을 들 수 있습니다.

위장 질환의 유병률 증가는 향후 분변 미생물총 이식(FMT) 시장 확대에 박차를 가할 것으로 예상됩니다. 위장(GI) 장애에는 식도, 위, 소장, 대장(결장), 직장 및 항문을 포함한 소화관에 영향을 미치는 다양한 질환이 포함됩니다. 소화기 질환 증가 요인으로는 스트레스 증가, 좌식 생활, 가공식품 섭취 증가 등을 들 수 있습니다. 분변 미생물총 이식은 소화관 질환 환자의 건강한 장내 세균을 복원하기 위해 특히 재발성 클로스트리디움 디피실 감염을 치료하는 데 활용되고 있습니다. 예를 들어, 비영리 단체인 Crohn's and Colitis Canada의 보고서에 따르면, 캐나다의 염증성 장질환(IBD) 환자 수는 빠르게 증가하고 있으며, 2023년 32,600명(인구의 0.8%)에서 2035년 47만 명(인구의 1.1%)으로 증가할 것으로 예측했습니다. 2023년에는 11,000명(약 48분당 1명)이 새로 진단받고, 2035년에는 14,000명(약 38분당 1명)으로 증가할 것으로 예측되고 있습니다. 결과적으로 소화기 질환의 유병률 증가는 분변 미생물총 이식(FMT) 시장의 성장을 가속하는 중요한 요인으로 작용하고 있습니다.

분변 미생물총 이식(FMT) 시장의 주요 기업들은 소화기 질환의 치료 효과를 개선하기 위해 미생물총 기반 생물학적 치료와 같은 혁신적인 솔루션 개발에 주력하고 있습니다. 미생물총 기반 생체 치료는 다양한 질병을 치료하기 위해 장내 미생물총을 회복하거나 변화시키는 치료제로 살아있는 미생물을 사용하는 것을 포함합니다. 예를 들어, 2022년 11월 스위스에 본사를 둔 바이오 제약회사 Ferring Pharmaceuticals는 미국 식품의약국(FDA)으로부터 REBYOTA(대변 미생물총, live-jslm)의 승인을 받았습니다. 이 새로운 동종 최초의 미생물군집 기반 바이오 치료제는 재발성 CDI에 대한 항생제 치료 후 18세 이상 환자에서 클로스트리디움 디피실 감염(CDI)의 재발을 예방하기 위해 고안되었습니다. 클로스트리디움 디피실(C. difficile) 감염 치료 후 재발을 예방하는 데 특히 적합합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 거시경제 시나리오

제5장 세계 시장 규모와 성장

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 주요 기업 및 혁신 기업

제32장 경쟁 벤치마킹

제33장 경쟁 대시보드

제34장 주요 인수합병(M&A)

제35장 향후 전망과 잠재적인 분석

제36장 부록

LSH
영문 목차

영문목차

Fecal microbiota transplantation (FMT) is a medical procedure where a healthy donor's fecal material is transplanted into a recipient's gastrointestinal tract to restore the balance of beneficial microorganisms in the gut. This procedure is typically used to treat conditions where the gut microbiota is disrupted, such as recurrent clostridium difficile infection (CDI) that does not respond to standard treatments.

The main types of fecal microbiota transplantation (FMT) are fermentation, fresh, and cryopreservation. Fermentation in Fecal Microbiota Transplantation (FMT) refers to the process by which gut bacteria break down complex carbohydrates and fibers in the gastrointestinal tract, producing short-chain fatty acids and other metabolites that promote gut health. Donor types include stool-derived, fecal-derived, and whole-microbiome derived, used to treat various conditions such as Clostridioides difficile infection, inflammatory bowel disease, metabolic syndrome, and others. It is administered through oral, rectal, nasogastric, and colon capsule routes. The end users include hospitals, specialty clinics, and others.

The fecal microbiota transplantation (FMT) market research report is one of a series of new reports from The Business Research Company that provides fecal microbiota transplantation (FMT) market statistics, including the fecal microbiota transplantation (FMT) industry's global market size, regional shares, competitors with a fecal microbiota transplantation (FMT) market share, detailed fecal microbiota transplantation (FMT) market segments, market trends and opportunities, and any further data you may need to thrive in the fecal microbiota transplantation (FMT) industry. This fecal microbiota transplantation (FMT) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The fecal microbiota transplantation (FMT) market size has grown strongly in recent years. It will grow from $0.80 billion in 2023 to $0.85 billion in 2024 at a compound annual growth rate (CAGR) of 6.7%. The growth during the historic period can be attributed to a rising awareness of the gut microbiome, expanding therapeutic applications, the growth of personalized medicine, adoption in gastroenterology practices, a higher number of clinical trials, and increased funding and investments.

The fecal microbiota transplantation (FMT) market size is expected to see strong growth in the next few years. It will grow to $1.12 billion in 2028 at a compound annual growth rate (CAGR) of 7.0%. The growth during the forecast period can be attributed to the rising incidence of Clostridium difficile infections (CDI), an increasing prevalence of inflammatory bowel diseases, heightened research and development activities, a growing geriatric population, and expanding healthcare infrastructure. Key trends during this period include the creation of standardized protocols for donor screening and stool preparation, advancements in microbiome analysis, improved stool processing technologies, innovative delivery methods, and the development of synthetic or standardized microbiota-based products.

The increasing incidence of gastrointestinal disorders is anticipated to fuel the expansion of the fecal microbiota transplantation (FMT) market in the future. Gastrointestinal (GI) disorders encompass a variety of conditions that impact the gastrointestinal tract, which includes the esophagus, stomach, small intestine, large intestine (colon), rectum, and anus. Factors contributing to the rise in GI disorders include heightened stress levels, sedentary habits, and a greater intake of processed foods. Fecal microbiota transplantation is utilized to restore healthy gut bacteria in patients with gastrointestinal disorders, particularly for the treatment of recurrent Clostridioides difficile infections. For example, Crohn's and Colitis Canada, a non-profit organization, reported that the number of individuals with inflammatory bowel disease (IBD) in Canada is rapidly increasing, projected to rise from 322,600 in 2023 (0.8% of the population) to 470,000 by 2035 (1.1% of the population). In 2023, 11,000 new cases are expected to be diagnosed (approximately one every 48 minutes), with this number increasing to 14,000 by 2035 (approximately one every 38 minutes). Consequently, the growing prevalence of gastrointestinal disorders is a significant factor driving the growth of the fecal microbiota transplantation (FMT) market.

Leading companies in the fecal microbiota transplantation (FMT) market are concentrating on developing innovative solutions, such as microbiota-based live biotherapeutics, to improve treatment effectiveness for gastrointestinal disorders. Microbiota-based live biotherapeutics involve using live microorganisms as therapeutic agents to restore or alter the gut microbiome for treating various diseases. For example, in November 2022, Ferring Pharmaceuticals, a biopharmaceutical company based in Switzerland, received approval from the US Food and Drug Administration (FDA) for REBYOTA (fecal microbiota, live-jslm). This novel, first-in-class microbiota-based live biotherapeutic is designed to prevent the recurrence of Clostridioides difficile infection (CDI) in individuals aged 18 and older, following antibiotic treatment for recurrent CDI. REBYOTA is specifically indicated for preventing the recurrence of Clostridioides difficile (C. difficile) infection in this age group after such treatment.

In October 2022, SYNLAB Group, a Germany-based provider of medical diagnostic services, formed a partnership with Microba to improve access to advanced microbiome analysis and enhance patient health management. The collaboration aims to expand the availability of the myBIOME test across Europe and Latin America, building on its success in Spain and Colombia. Microba, an Australia-based biotechnology company, specializes in fecal microbiota transplantation (FMT) research and application.

Major companies operating in the fecal microbiota transplantation (FMT) market are Ferring Pharmaceuticals, Johns Hopkins Medicine, Seres Therapeutics, Taconic Biosciences, Enterome, Rebiotix Inc, Finch Therapeutics Group Inc, Locus Biosciences, Yeda Research and Development Co. Ltd, Microbiotica Limited, CosmosID Inc, AOBiome, Synthetic Biologics Inc., Osel Inc., OpenBiome, Asia Microbiota Bank, Taymount Clinic, MicroBiome Therapeutics LLC, MaaT Pharma SA, Kallyope

North America was the largest region in the fecal microbiota transplantation (FMT) market in 2023. The regions covered in the fecal microbiota transplantation (FMT) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the fecal microbiota transplantation (FMT) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The fecal microbiota transplantation (FMT) market consists of revenues earned by entities by providing services such as donor screening and testing, microbiome assessment, stool collection, processing and preparation, endoscopic delivery, clinical monitoring, and symptom management. The market value includes the value of related goods sold by the service provider or included within the service offering. The fecal microbiota transplantation (FMT) market also includes sales of oral capsules, colonoscopy-based FMT, nasogastric or nasoduodenal tube and lyophilized (freeze-dried) stool. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Fecal Microbiota Transplantation (FMT) Global Market Report 2024 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on fecal microbiota transplantation (FMT) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for fecal microbiota transplantation (FMT) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The fecal microbiota transplantation (FMT) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The impact of sanctions, supply chain disruptions, and altered demand for goods and services due to the Russian Ukraine war, impacting various macro-economic factors and parameters in the Eastern European region and its subsequent effect on global markets.

The impact of higher inflation in many countries and the resulting spike in interest rates.

The continued but declining impact of COVID-19 on supply chains and consumption patterns.

Scope

Table of Contents

1. Executive Summary

2. Fecal Microbiota Transplantation (FMT) Market Characteristics

3. Fecal Microbiota Transplantation (FMT) Market Trends And Strategies

4. Fecal Microbiota Transplantation (FMT) Market - Macro Economic Scenario

5. Global Fecal Microbiota Transplantation (FMT) Market Size and Growth

6. Fecal Microbiota Transplantation (FMT) Market Segmentation

7. Fecal Microbiota Transplantation (FMT) Market Regional And Country Analysis

8. Asia-Pacific Fecal Microbiota Transplantation (FMT) Market

9. China Fecal Microbiota Transplantation (FMT) Market

10. India Fecal Microbiota Transplantation (FMT) Market

11. Japan Fecal Microbiota Transplantation (FMT) Market

12. Australia Fecal Microbiota Transplantation (FMT) Market

13. Indonesia Fecal Microbiota Transplantation (FMT) Market

14. South Korea Fecal Microbiota Transplantation (FMT) Market

15. Western Europe Fecal Microbiota Transplantation (FMT) Market

16. UK Fecal Microbiota Transplantation (FMT) Market

17. Germany Fecal Microbiota Transplantation (FMT) Market

18. France Fecal Microbiota Transplantation (FMT) Market

19. Italy Fecal Microbiota Transplantation (FMT) Market

20. Spain Fecal Microbiota Transplantation (FMT) Market

21. Eastern Europe Fecal Microbiota Transplantation (FMT) Market

22. Russia Fecal Microbiota Transplantation (FMT) Market

23. North America Fecal Microbiota Transplantation (FMT) Market

24. USA Fecal Microbiota Transplantation (FMT) Market

25. Canada Fecal Microbiota Transplantation (FMT) Market

26. South America Fecal Microbiota Transplantation (FMT) Market

27. Brazil Fecal Microbiota Transplantation (FMT) Market

28. Middle East Fecal Microbiota Transplantation (FMT) Market

29. Africa Fecal Microbiota Transplantation (FMT) Market

30. Fecal Microbiota Transplantation (FMT) Market Competitive Landscape And Company Profiles

31. Fecal Microbiota Transplantation (FMT) Market Other Major And Innovative Companies

32. Global Fecal Microbiota Transplantation (FMT) Market Competitive Benchmarking

33. Global Fecal Microbiota Transplantation (FMT) Market Competitive Dashboard

34. Key Mergers And Acquisitions In The Fecal Microbiota Transplantation (FMT) Market

35. Fecal Microbiota Transplantation (FMT) Market Future Outlook and Potential Analysis

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기